合成和表征ULK1/2激酶抑制剂,抑制自和Upregulate表达主要基因相容性复合体I的合成和表征,用于治疗非小细胞肺癌
bioRxiv : the preprint server for biology
|September 18, 2025
概括
新的双重ULK1/2抑制剂SBP-5147和SBP-7501显示出对治疗非小细胞肺癌 (NSCLC) 的前景. 这些化合物具有细胞毒性,抑制自,并与SBP-7455.5相比提供更好的口服暴露.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 自抑制是一种潜在的癌症治疗方法,包括非小细胞肺癌 (NSCLC).
- 之前的研究确定了SBP-7455,它是unc-51-like激酶1 (ULK1) 和ULK2的双重抑制剂,对三阴性乳腺癌 (TNBC) 有效.
研究的目的:
- 设计,合成和描述新的双ULK1/2抑制剂SBP-5147和SBP-7501.
- 评估这些新的抑制剂对NSCLC细胞的疗效及其对自流的影响.
主要方法:
- 对SBP-5147和SBP-7501的化学合成和表征.
- 对NSCLC细胞的细胞毒性测定.
- 在A549细胞中自流抑制的评估.
- 口服暴露的药理动力学评估.
主要成果:
- SBP-5147和SBP-7501对NSCLC细胞表现出细胞毒性.
- 这两种化合物都抑制了A549细胞中的自流.
- 与较低剂量的SBP-7455相比,SBP-5147和SBP-7501表现出更高的口服暴露.
- SBP-5147在NSCLC细胞中增加主要组织相容性复合体 (MHC) I类表达,这表明克服免疫疗法耐药性的潜力.
结论:
- SBP-5147和SBP-7501是强大的双ULK1/2抑制剂,具有作为NSCLC抗癌剂的潜力.
- 这些抑制剂可以通过调节MHC I类表达来增强免疫疗法.
- ULK1/2 抑制剂是一个可行的治疗策略,单独或与现有治疗相结合,用于癌症管理.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K